Qed Therapeutics, A Bridgebio Company
Clinical trials sponsored by Qed Therapeutics, A Bridgebio Company, explained in plain language.
-
New drug aims to boost growth in kids with rare bone disorder
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called infigratinib in 24 children with hypochondroplasia, a condition that causes short stature. The goal is to see if it can safely improve growth rate. The study has two phases: first, all children get the drug, then some get a placebo to compare result…
Phase: PHASE2, PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for children with dwarfism: Long-Term drug trial launches
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of an oral drug called infigratinib in children with achondroplasia, the most common form of dwarfism. About 300 children who previously took part in a related study or are new to the treatment will receive the drug for seve…
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for kids with hypochondroplasia: Long-Term drug trial underway
Disease control ENROLLING_BY_INVITATIONThis study is for children with hypochondroplasia, a condition that causes short stature. It tests a drug called infigratinib over the long term to see if it is safe and helps with growth. Participants must have already completed a related earlier study. The goal is to understand…
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated May 13, 2026 16:00 UTC